Dragon Pharma, Europe
Helios
Injection · 5.8 mg/ml · 10 ml
$31.00
Compound ID
Clenbuterol Hydrochloride / Yohimbine Hydrochloride
Dosage
3.4–12.16 mg/day
Concentration
30 mcg Clenbuterol + 5.6 mg Yohimbine
Form
10 mL Vial × 5.8 mg
Half-life
48–72 hours
Shipping
Not available in this combination
Product overview
Dragon Pharma Helios — Injectable Clenbuterol & Yohimbine Blend for Stubborn Fat Loss
Dragon Pharma Helios is an advanced injectable thermogenic combining clenbuterol hydrochloride and yohimbine hydrochloride in a single lipolytic solution. Delivering 80mcg of clenbuterol and 5mg of yohimbine per milliliter, this formula targets resistant adipose tissue through dual receptor mechanisms. The injectable route bypasses hepatic first-pass metabolism, offering enhanced bioavailability compared to oral alternatives. Independent laboratory analysis confirms 65.50mcg of clenbuterol and 6.53mg of yohimbine per milliliter, ensuring potent, predictable activity for contest preparation and aggressive cutting phases.
What is Dragon Pharma Helios?
This injectable fat burner contains two synergistic compounds in one sterile solution. Clenbuterol acts as a potent beta-2 adrenergic agonist, while yohimbine functions as an alpha-2 adrenergic antagonist. Together they create a multi-pathway attack on stored body fat.
Originally conceptualized for advanced body recomposition, this blend is specifically designed to address stubborn fat deposits that resist conventional diet and exercise. The subcutaneous or intramuscular administration route delivers both agents directly into systemic circulation.
Key Benefits / Effects
- Synergistic Thermogenesis: The beta-2 agonist elevates core temperature and metabolic rate, while the alpha-2 antagonist unlocks fat from receptor-dense stubborn areas, creating a powerful combined lipolytic effect.
- Targeted Stubborn Fat Mobilization: Yohimbine specifically blocks alpha-2 receptors in resistant zones like the lower abdomen, love handles, and glutes, allowing fat oxidation from areas typically unresponsive to caloric deficits.
- Enhanced Bioavailability: The injectable format avoids digestive degradation and first-pass liver metabolism, delivering higher active concentrations of both compounds compared to oral administration.
- Sustained Energy Output: Users report pronounced stimulant effects that support intense training sessions and combat fatigue during severe caloric restriction.
- Appetite Suppression: Both active ingredients contribute to reduced hunger signals, simplifying dietary adherence during aggressive pre-contest protocols.
- Lean Mass Preservation: The clenbuterol component exhibits mild anti-catabolic properties that help protect muscle tissue during steep energy deficits.
How Dragon Pharma Helios Works
Clenbuterol binds to beta-2 adrenergic receptors, activating adenylate cyclase and increasing intracellular cyclic AMP. This cascade stimulates hormone-sensitive lipase, breaking down triglycerides into free fatty acids for energy utilization.
Yohimbine simultaneously occupies alpha-2 adrenergic receptors on adipocytes in stubborn fat regions. Under normal conditions, these receptors inhibit lipolysis. By blocking them, yohimbine removes the biological brake on fat release from resistant areas.
The injectable delivery ensures both compounds reach circulation rapidly and intact. This dual-receptor approach attacks fat stores from both metabolic acceleration and regional release angles simultaneously.
Usage Information
This lipolytic injection is supplied as a sterile solution containing both active compounds. Administration is typically subcutaneous into fatty tissue or intramuscular, with strict site rotation to prevent tissue irritation.
Begin with 0.1mL daily, providing 8mcg clenbuterol and 0.5mg yohimbine. Assess tolerance for several days before increasing. Intermediate users often progress to 0.2–0.3mL daily. Advanced protocols may reach 0.5mL, though side effects escalate significantly beyond this range.
Dose in the morning or split between morning and early afternoon. Avoid evening administration due to insomnia risk. Cycle for two weeks followed by a two-week break to maintain receptor sensitivity.
Quality & Manufacturing
Independent laboratory verification confirms 65.50mcg of clenbuterol and 6.53mg of yohimbine per milliliter. This demonstrates both consistency and slightly exceeded potency claims.
Manufacturing under sterile conditions ensures a stable, contaminant-free solution suitable for injection. For a combination product requiring precise ratio balance, verified analytical data guarantees each milliliter delivers the expected dual-receptor pharmacological activity.
Possible Side Effects / Safety Information
- Cardiovascular Strain: Both compounds elevate heart rate and blood pressure significantly. Individuals with pre-existing cardiac conditions should avoid this product entirely.
- Stimulant Overstimulation: Anxiety, tremors, and nervous energy are common, particularly during initial use or dose escalation.
- Sleep Disruption: The long half-life of clenbuterol combined with yohimbine's stimulant properties makes insomnia likely if dosed after mid-afternoon.
- Electrolyte Depletion: Taurine and potassium levels may drop, causing muscle cramps. Daily taurine supplementation and potassium-rich nutrition are mandatory.
- Injection Site Reactions: Localized redness, swelling, or discomfort may occur. Proper sterile technique and site rotation minimize this risk.
- Headaches and Nausea: Central nervous system stimulation can produce cephalalgia and mild stomach upset during the adaptation phase.
Why Choose Dragon Pharma Helios?
The combination of beta-2 agonism and alpha-2 antagonism in a single injectable format represents an advanced approach to body recomposition. Oral fat burners cannot replicate the bioavailability or targeted receptor synergy this solution provides.
Verified dual-ingredient potency ensures users receive the precise pharmacological balance required for stubborn fat mobilization. For competitors and advanced athletes seeking the final level of definition, this injectable thermogenic offers a streamlined, potent alternative to stacking separate oral compounds.
Lab Report
Lab Report: 48.4 mg/ml
20 Nov 2025
5.8 mg/ml of label claim
| Analysis Date | 2025-11-20 |
| Lot / Batch ID | #HELIBG9 |
| Measured Potency | 48.4 mg |
| Quality Assessment | Potency verified, purity passed, heavy metals passed. |
| Current Production Batch | Latest Batch |
Verify this result with your scratch-off code at the DPStore register.
Great product and results thus far. Down 7lbs in 2 weeks!
Product FAQ
Questions, answered
The injectable route bypasses gastrointestinal absorption and hepatic first-pass metabolism, delivering higher bioavailable concentrations of both clenbuterol and yohimbine directly into circulation. This often produces more pronounced and predictable thermogenic effects compared to oral formats.
Yohimbine is an alpha-2 adrenergic antagonist that blocks receptors responsible for inhibiting fat release in stubborn areas. While clenbuterol accelerates overall metabolism, yohimbine specifically unlocks fat from resistant zones like the lower abdomen and hips. Together they address both total energy expenditure and regional fat mobilization.
Start with 0.1mL injected once daily in the morning. This delivers 8mcg of clenbuterol and 0.5mg of yohimbine. Increase gradually every few days based on tolerance. Most users find 0.2–0.3mL daily effective. Do not exceed 0.5mL without extensive prior experience.
Subcutaneous injection into fatty deposits like the abdomen or glutes is common and may enhance local fat mobilization. However, rotate sites with every injection to prevent tissue irritation or localized reactions. Intramuscular administration is also acceptable.
Follow a two-week on, two-week off protocol. Continuous use causes beta-receptor downregulation, reducing clenbuterol efficacy over time. The off period restores receptor sensitivity and maintains long-term fat-burning potential.
Yes. Clenbuterol depletes taurine stores, leading to painful muscle cramps. Supplement 3–5 grams of taurine daily. Consume potassium-rich foods like bananas, spinach, and avocados to support electrolyte balance and prevent cramping.
Female athletes can use this combination at significantly lower doses, often starting at 0.05mL daily. Yohimbine can cause pronounced anxiety in some women, so conservative titration is essential. Discontinue immediately if excessive jitteriness or heart palpitations occur.
This is an advanced thermogenic combination. Beginners should first establish tolerance with standalone oral clenbuterol before attempting a dual-compound injectable. The cardiovascular and neurological demands require prior stimulant experience.
Injection avoids digestive breakdown and liver filtration, allowing both compounds to reach target tissues at higher concentrations. This improved pharmacokinetic profile often translates to faster onset, stronger effects, and more consistent blood levels.
Advanced competitors sometimes combine this injectable thermogenic with T3 for extreme metabolic acceleration. This stack significantly increases catabolism risk and cardiac strain. A mandatory muscle-preserving anabolic base and close medical monitoring are required.
Stubborn fat deposits are rich in alpha-2 receptors that actively inhibit lipolysis. Even in a steep caloric deficit, these receptors prevent fat release. Yohimbine neutralizes this blockade, allowing stored triglycerides to enter the bloodstream for oxidation.
Underdosed yohimbine renders the alpha-2 blockade ineffective, while excessive clenbuterol creates dangerous cardiovascular stress. Verified analytical data confirming both compounds at precise ratios ensures safe, predictable dual-receptor pharmacology.
